‹ All episodes

The BioInsights Podcast

Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development

June 09, 2023 Paul Byrne Season 2 Episode 6
The BioInsights Podcast
Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
Chapters
Chapters
1:17
You've been working in gene therapy for a long time now. What do you see as the key learnings of the industry related to bioanalysis of in vivo therapeutic approaches?
6:24
What would you identify as the key commonalities – and the important differences – that exist in approaching bioanalysis of ex vivo gene-modified cell therapies?
9:25
How is the field of gene therapy evolving, and what new therapies and delivery methods do you see on the horizon?
13:43
Why are biodistribution, vector shedding, and transgene expression are such critical factors for ensuring the safety of cell and gene therapies?
15:27
Can you outline the key challenges associated with assessing and monitoring biodistribution and vector shedding?
20:13
What new approaches are being developed to address these challenges? And what impact is that introduction of digital PCR having?
27:18
How can the insights and best practices we've discussed today be applied to specific R&D efforts? What would your key advice be for our listeners who are working in this space?
Info
The BioInsights Podcast
Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
Jun 09, 2023 Season 2 Episode 6
Paul Byrne

In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.

Share
Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +
Show Notes Chapter Markers

In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.

1:17
You've been working in gene therapy for a long time now. What do you see as the key learnings of the industry related to bioanalysis of in vivo therapeutic approaches?
6:24
What would you identify as the key commonalities – and the important differences – that exist in approaching bioanalysis of ex vivo gene-modified cell therapies?
9:25
How is the field of gene therapy evolving, and what new therapies and delivery methods do you see on the horizon?
13:43
Why are biodistribution, vector shedding, and transgene expression are such critical factors for ensuring the safety of cell and gene therapies?
15:27
Can you outline the key challenges associated with assessing and monitoring biodistribution and vector shedding?
20:13
What new approaches are being developed to address these challenges? And what impact is that introduction of digital PCR having?
27:18
How can the insights and best practices we've discussed today be applied to specific R&D efforts? What would your key advice be for our listeners who are working in this space?